These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 38286960)
1. Artificial Intelligence in Liver Diseases: Recent Advances. Lu F; Meng Y; Song X; Li X; Liu Z; Gu C; Zheng X; Jing Y; Cai W; Pinyopornpanish K; Mancuso A; Romeiro FG; Méndez-Sánchez N; Qi X Adv Ther; 2024 Mar; 41(3):967-990. PubMed ID: 38286960 [TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence for hepatitis evaluation. Liu W; Liu X; Peng M; Chen GQ; Liu PH; Cui XW; Jiang F; Dietrich CF World J Gastroenterol; 2021 Sep; 27(34):5715-5726. PubMed ID: 34629796 [TBL] [Abstract][Full Text] [Related]
3. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Yu JH; Lee HA; Kim SU Clin Mol Hepatol; 2023 Feb; 29(Suppl):S136-S149. PubMed ID: 36503205 [TBL] [Abstract][Full Text] [Related]
4. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. Kamada Y; Nakamura T; Isobe S; Hosono K; Suama Y; Ohtakaki Y; Nauchi A; Yasuda N; Mitsuta S; Miura K; Yamamoto T; Hosono T; Yoshida A; Kawanishi I; Fukushima H; Kinoshita M; Umeda A; Kinoshita Y; Fukami K; Miyawaki T; Fujii H; Yoshida Y; Kawanaka M; Hyogo H; Morishita A; Hayashi H; Tobita H; Tomita K; Ikegami T; Takahashi H; Yoneda M; Jun DW; Sumida Y; Okanoue T; Nakajima A; J Gastroenterol; 2023 Feb; 58(2):79-97. PubMed ID: 36469127 [TBL] [Abstract][Full Text] [Related]
5. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma. Alqahtani SA; Chan WK; Yu ML Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203 [TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence model with deep learning in nonalcoholic fatty liver disease diagnosis: genetic based artificial neural networks. Ülger Y; Delik A Nucleosides Nucleotides Nucleic Acids; 2023; 42(5):398-406. PubMed ID: 36448439 [TBL] [Abstract][Full Text] [Related]
7. Artificial intelligence in the diagnosis and management of hepatocellular carcinoma. Sato M; Tateishi R; Yatomi Y; Koike K J Gastroenterol Hepatol; 2021 Mar; 36(3):551-560. PubMed ID: 33709610 [TBL] [Abstract][Full Text] [Related]
8. Developing deep learning-based strategies to predict the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease from electronic health records. Li Z; Lan L; Zhou Y; Li R; Chavin KD; Xu H; Li L; Shih DJH; Jim Zheng W J Biomed Inform; 2024 Apr; 152():104626. PubMed ID: 38521180 [TBL] [Abstract][Full Text] [Related]
9. [New advances of artificial intelligence in the diagnosis of non-alcoholic fatty liver disease]. Li XH; Liu F; Rao HY Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):443-446. PubMed ID: 35545572 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Li B; Zhang C; Zhan YT Can J Gastroenterol Hepatol; 2018; 2018():2784537. PubMed ID: 30065915 [TBL] [Abstract][Full Text] [Related]
11. Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023). Zamanian H; Shalbaf A; Zali MR; Khalaj AR; Dehghan P; Tabesh M; Hatami B; Alizadehsani R; Tan RS; Acharya UR Comput Methods Programs Biomed; 2024 Feb; 244():107932. PubMed ID: 38008040 [TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125 [TBL] [Abstract][Full Text] [Related]
13. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831 [TBL] [Abstract][Full Text] [Related]
14. Application of artificial intelligence in chronic liver diseases: a systematic review and meta-analysis. Decharatanachart P; Chaiteerakij R; Tiyarattanachai T; Treeprasertsuk S BMC Gastroenterol; 2021 Jan; 21(1):10. PubMed ID: 33407169 [TBL] [Abstract][Full Text] [Related]
15. Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. Dinani AM; Kowdley KV; Noureddin M Hepatology; 2021 Oct; 74(4):2233-2240. PubMed ID: 33928671 [TBL] [Abstract][Full Text] [Related]
16. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis. Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730 [TBL] [Abstract][Full Text] [Related]